10:10 AM EST - Medexus Pharmaceuticals : Recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Programs will now reimburse eligible claims made for Trecondyv®, subject to satisfaction of any relevant conditions set out in the agreements. Medexus Pharmaceuticals
shares T.MDP are trading up $0.03 at $3.83.
